Bank of America’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-50,000
| Closed | -$315K | – | 8572 |
|
|
2025
Q2 | $315K | Buy |
+50,000
| New | +$331K | ﹤0.01% | 5965 |
|
|
2025
Q1 | – | Sell |
-10,000
| Closed | -$80.4K | – | 8467 |
|
|
2024
Q4 | $80.4K | Hold |
10,000
| – | – | ﹤0.01% | 6488 |
|
|
2024
Q3 | $126K | Sell |
10,000
-119,200
| -92% | -$1.54M | ﹤0.01% | 6225 |
|
|
2024
Q2 | $1.64M | Sell |
129,200
-440,100
| -77% | -$4.43M | ﹤0.01% | 4572 |
|
|
2024
Q1 | $2.72M | Buy |
569,300
+132,600
| +30% | +$615K | ﹤0.01% | 4201 |
|
|
2023
Q4 | $2.1M | Buy |
436,700
+89,200
| +26% | +$546K | ﹤0.01% | 4356 |
|
|
2023
Q3 | $2.52M | Sell |
347,500
-623,900
| -64% | -$4.99M | ﹤0.01% | 4048 |
|
|
2023
Q2 | $7.22M | Sell |
971,400
-6,400
| -0.7% | -$50.3K | ﹤0.01% | 3034 |
|
|
2023
Q1 | $6.78M | Sell |
977,800
-274,600
| -22% | -$2.53M | ﹤0.01% | 3223 |
|
|
2022
Q4 | $12.9M | Buy |
1,252,400
+444,800
| +55% | +$7.85M | ﹤0.01% | 2442 |
|
|
2022
Q3 | $14.7M | Sell |
807,600
-73,000
| -8% | -$3.16M | ﹤0.01% | 2225 |
|
|
2022
Q2 | $45.3M | Buy |
880,600
+249,100
| +39% | +$12.9M | 0.01% | 1330 |
|
|
2022
Q1 | $46.5M | Buy |
631,500
+431,900
| +216% | +$38.5M | ﹤0.01% | 1422 |
|
|
2021
Q4 | $28.6M | Buy |
199,600
+191,500
| +2,364% | +$32.9M | ﹤0.01% | 1876 |
|
|
2021
Q3 | $1.68M | Sell |
8,100
-42,400
| -84% | -$9.34M | ﹤0.01% | 4604 |
|
|
2021
Q2 | $10.7M | Buy |
+50,500
| New | +$9.25M | ﹤0.01% | 2764 |
|
|
2021
Q1 | – | Sell |
-10,000
| Closed | -$1.11M | – | 7664 |
|
|
2020
Q4 | $1.11M | Sell |
10,000
-12,400
| -55% | -$1.32M | ﹤0.01% | 4415 |
|
|
2020
Q3 | $2.43M | Sell |
22,400
-42,600
| -66% | -$5.19M | ﹤0.01% | 3513 |
|
|
2020
Q2 | $5.42M | Sell |
65,000
-50,700
| -44% | -$1.94M | ﹤0.01% | 2758 |
|
|
2020
Q1 | $1.57M | Buy |
+115,700
| New | +$979K | ﹤0.01% | 3664 |
|
|
2019
Q2 | – | Sell |
-25,000
| Closed | -$275K | – | 7338 |
|
|
2019
Q1 | $275K | Buy |
+25,000
| New | +$789K | ﹤0.01% | 5365 |
|
|
2015
Q1 | – | Sell |
-305
| Closed | -$36K | – | 7403 |
|
|
2014
Q4 | $36K | Sell |
305
-160
| -34% | -$16.7K | ﹤0.01% | 6522 |
|
|
2014
Q3 | $39K | Sell |
465
-30
| -6% | -$2.71K | ﹤0.01% | 6672 |
|
|
2014
Q2 | $46K | Buy |
495
+215
| +77% | +$18.9K | ﹤0.01% | 6712 |
|
|
2014
Q1 | $25K | Buy |
+280
| New | +$31.3K | ﹤0.01% | 6804 |
|
Other funds holding NVAX
SCM
VPM
VCM
S
Bank of America's NVAX Position: Q1 2026 in Review
Bank of America reduced its Novavax (NVAX) stake by 20% in Q1 2026, selling an estimated $15M and leaving 6,637,213 shares worth $54M. The position accounts for ﹤0.01% of the portfolio, ranked #1535.
Bank of America first reported a position in NVAX in Q2 2013 and has held it in 52 quarters since. The position peaked at $55.7M in Q4 2025. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.
- Bank of America held 6,637,213 shares of Novavax worth $54M as of Q1 2026.
- Bank of America sold 1,653,452 Novavax shares in Q1 2026, an estimated $15M.
- Novavax made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1535 holding.
- Bank of America first reported a position in Novavax in Q2 2013 and has held it in 52 quarters since.
- Bank of America's Novavax position peaked at $55.7M in Q4 2025.
- 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.